Navigation Links
Octapharma Targets Primary Immune Deficiency Research With Grant for The Mount Sinai Medical Center
Date:1/18/2011

NEW YORK and HOBOKEN, N.J., Jan. 18, 2011 /PRNewswire/ -- Octapharma USA today announced the second grant recipient of the Octapharma 25th Anniversary Grants Program is the Clinical Immunology Research Laboratory at The Mount Sinai Medical Center. The Octapharma Grants program supports clinical or pre-clinical research focused on human protein therapies in hematology, immune therapy, intensive care and emergency medicine.

Charlotte Cunningham-Rundles, M.D., Ph.D., Director of the Allergy Immunology and the Immunology Training Program and Director of the Immunodeficiency Clinic at The Mount Sinai Medical Center, is the lead investigator for a research project focused on distinguishing true Common Variable Immune Deficiencies (CVID) from disorders with more modest immune defects. Dr. Cunningham-Rundles has nearly 30 years experience with clinical immune deficiency disorders with a research focus of human immunodeficiency diseases and immuno-reconstitution.

Octapharma AG, one of the largest human protein products manufacturers in the world, launched the Octapharma Grants program last year in celebration of the biopharmaceutical company's 25th anniversary. The company's first ever grants program is only available to researchers based in the United States and is administered by Octapharma USA, the Swiss company's U.S. subsidiary.

"It is a pleasure to announce Octapharma's support for the valuable research being pursued by the Clinical Immunology Research group at The Mount Sinai Medical Center," said Octapharma USA President Flemming Nielsen. "Dr. Cunningham-Rundles is a well-recognized national leader in the field of clinical and laboratory immunology and we consider her research extremely important in understanding how to best diagnose and treat primary immune deficiency earlier and more effectively. The grant program and its second award will continue to advance Octapharma's firm commitment to the U.S. market, underscoring our commitment to provide patients with the safest, highest quality therapies available today."

CVID is a primary immune defect characterized by poor or absent production of immune globulins IgG, IgA and/or IgM. CVID is a type of primary immune deficiency disease with high clinical interest due to its prevalence, severity of complications, rate of hospitalizations and necessity for lifelong immune globulin therapy.  Unfortunately, using the available published criteria for diagnosing CVID, physicians have difficulty distinguishing this disease from milder immune defects of antibody production.  The difficulty of distinguishing between patient groups is medically important as subjects with validated CVID appear more likely to develop selected inflammatory complications which may require additional monitoring or treatment. Patients with more modest defects may be more exempt from these issues and could require different clinical surveillance.

"The aim of our research is to provide the medical community and patients with information and tools to distinguish the more clear cases of CVID from other milder antibody disorders," said Dr. Cunningham-Rundles. "By reviewing and analyzing clinical records and available laboratory data, we will work toward the development of a scoring system as a clinical tool.  With the large cohort of patients seen at The Mount Sinai Medical Center, the study may be able to determine if the immunologic and clinical differences seen in various defects can be distinguished."

The Octapharma Grants Committee has officially closed the second cycle of 2010 grant applications and has opened the first cycle for 2011 applications.  The deadline for the next cycle of 2011 submissions is March 31. Please visit www.octapharmagrants.com for a complete description of the grants program.

About the Octapharma Group

Headquartered in Lachen, Switzerland, Octapharma AG is one of the largest human protein products manufacturers in the world and has been committed to patient care and medical innovation for over 27 years. Octapharma's core business is the development, production and sale of high quality human protein therapies from both human plasma and human cell-lines, including immune globulin intravenous (IGIV). In the U.S., Octapharma's IGIV product, octagam®  (immune globulin intravenous [human] 5%), is used to treat disorders of the immune system, and Octapharma's Albumin (human)® is indicated for the restoration and maintenance of circulating blood volume. Octapharma's wilate® received orphan drug exclusivity from the U.S. Food and Drug Administration (FDA) for the treatment of von Willebrand disease (VWD). Octapharma employs over 4,000 people and has biopharmaceutical experience in 80 countries worldwide, including the United States, where Octapharma USA is located in Hoboken, N.J.  Octapharma operates two state-of-the-art production sites licensed by the FDA, providing a high level of production flexibility. For more information, please visit www.octapharma.com.

About the Clinical Immunology Research Laboratory, The Mount Sinai Medical Center

The Mount Sinai Medical Center encompasses both The Mount Sinai Hospital and Mount Sinai School of Medicine. Established in 1968, Mount Sinai School of Medicine is one of few medical schools embedded in a hospital in the United States. The Mount Sinai Medical Center has one of the largest programs in the country for treating patients with antibody defects, treating adult and pediatric patients from throughout the Northeast. The Clinical Immunology Research Laboratory focuses on the investigation of human immunodeficiency diseases and immuno-reconstitution and has been supported by research grants from U.S. Food and Drug Administration (FDA) and the National Institutes of Health (NIH).


'/>"/>
SOURCE Octapharma USA
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Octapharma Clinical Trial Begins in the U.S. and Germany Treating Hemophilia A Patients with First Recombinant Factor VIII Derived from a Human Cell-Line
2. Octapharma Accepting Applications for Research Grants Focused on Human Protein Therapies
3. Octapharma USA Launches Web Resource for von Willebrand Disease Healthcare Professionals and Patients
4. FDA Confirms Orphan Drug Exclusivity Approval for wilate®, Octapharma USAs New Therapy for Common Inherited Bleeding Disorder
5. Octapharma USA Announces Availability and Distributors for wilate®, the First Replacement Therapy Developed Specifically for von Willebrand Disease
6. Octapharma Receives Orphan Drug Exclusivity Approval for wilate(R) - A Replacement Therapy Developed Specifically for von Willebrand Disease
7. Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease
8. Octapharma Group and Fresenius Kabi Enter Into an Exclusive License, Development and Supply Agreement for a HESylated Recombinant Protein
9. Octapharma Targeting the Major Risk of Hemophilia Treatment - FVIII Antibodies
10. Octapharma Accepting Applications for Research Grants on Immunotherapy, Coagulation Disorders and Critical Care
11. Plasma Products Safe Despite Swine Influenza Outbreak, Assures International Biopharmaceutical Company Octapharma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... 2016  Syneron Medical Ltd. (NASDAQ: ELOS ... today that William Griffing , Chief Executive ... to participate in the Leerink Partners 5 th ... 2016 in New York City ... meet with the Mr. Griffing and will include ...
(Date:2/5/2016)... Feb. 5, 2016  As people age, it is ... of recommended screenings and tests that are linked with ... However, for the majority of aging individuals, hearing health ... For the 37.5 million American adults who report some ... to make hearing health a 2016 healthy aging priority.[1] ...
(Date:2/5/2016)...  Aralez Pharmaceuticals Inc. ("Aralez") today announced the completion ... Pharmaceuticals Canada Inc. ("Tribute") following approval of the transaction ... combined company will operate under Aralez Pharmaceuticals Inc. ("Aralez"), ... Canada , Ireland ... the terms of the Agreement and Plan of Merger ...
Breaking Medicine Technology:
(Date:2/7/2016)... (PRWEB) , ... February 07, 2016 , ... ... prolapse with the latest techniques and the most minimally invasive approaches. , Women ... prolapse, particularly after menopause. Other risk factors include surgery to the pelvic floor, ...
(Date:2/7/2016)... , ... February 07, 2016 , ... ... program. MyDecision™ empowers employers and organizations with the tools and information to lower ... three elements to cut the cost of providing employee healthcare benefits by as ...
(Date:2/6/2016)... ... February 06, 2016 , ... ... 5000 PERIOPERATIVE NURSES EXPECTED AT AORN SURGICAL CONFERENCE & EXPO , WHAT: ... world with an estimated 5000 perioperative nurses in attendance to study the ...
(Date:2/6/2016)... ... February 06, 2016 , ... With the FCPX ... warm color grades to their footage. A LUT is a Lookup Table that contains ... the corresponding color indicated by the table. By manipulating each pixel, LUT's can change ...
(Date:2/6/2016)... ... 06, 2016 , ... Research has shown that building shame ... frequency and level of relapse. , At the 2016 iaedp Symposium, ... explore the critical tasks of the recovery phase and beyond including relapse prevention ...
Breaking Medicine News(10 mins):